AI
Thursday, August 26, 2021 10:43:28 AM
>>> 10 Best Psychedelic Stocks to Buy Now
Insider Monkey
by Usman Kabir
July 14, 2021
https://finance.yahoo.com/news/10-best-psychedelic-stocks-buy-165743252.html
Psychedelic treatments for mental health disorders like depression, anxiety, and post-traumatic stress have revolutionized the industry in the past few years, helping the market for the novel therapies to grow from $2 billion in 2019, as per a report by Data Bridge Market Research, to almost $5 billion in 2020, according to a study by Research and Markets. The sector offers explosive growth potential, evidenced by the recent positive coverage of psychedelic stocks by investment research firms like Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald.
Some of the companies already making a big splash in the as yet small sector include COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), and Seelos Therapeutics, Inc. (NASDAQ: SEEL), among others. COMPASS Pathways plc (NASDAQ: CMPS) and Atai Life Sciences N.V. (NASDAQ: ATAI) recently debuted on the stock market, fetching billion dollar valuations, while Seelos Therapeutics, Inc. (NASDAQ: SEEL) has been soaring in trading the past few days on the back of positive results from a clinical study.
The success of these firms in the psychedelic market has attracted the attention of industry giants like Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK). These biopharma companies market different kinds of drugs for mental health disorders and sense a business opportunity as novel treatments for depression and anxiety become more widely accepted in the United States.
Investments in psychedelic startups have also increased in the past few months, with investors flocking to early stage psychedelic firms that are working on innovative new technologies to help psychedelics become more mainstream. Research institutions, like the Center for Psychedelic and Consciousness Research at John Hopkins University in Baltimore, which has already published more than 50 research papers on the subject, have also contributed to the industry. However, despite these advances, psychedelics remain a niche market in the pharma sector.
Investors looking to invest in the industry should be wary of certain challenges that the psychedelic companies will have to negotiate before unleashing their true growth potential. These challenges include an uphill legal battle to get approval for use of psychedelic substances in new drugs, a capacity-building campaign in the wider public to debunk the myths and stigma surrounding the use of psychedelics, as well as financial hurdles that an industry still in its infancy might face as it struggles for wider recognition.
The psychedelic industry has the potential to disrupt the biopharma sector in the coming years much like the rise of fintech has transformed the finance world. The entire hedge fund industry is feeling the reverberations of the changing financial landscape. Its reputation has been tarnished in the last decade, during which its hedged returns couldn’t keep up with the unhedged returns of the market indices.
With this context in mind, here is our list of the 10 best psychedelic stocks to buy now. These were ranked keeping in mind basic business fundamentals, hedge fund sentiment, and analyst ratings for each.
Best Psychedelic Stocks to Buy Now
10. Small Pharma Inc. (OTC: DMTTF)
Small Pharma Inc. (OTC: DMTTF) is placed tenth on our list of 10 best psychedelic stocks to buy now. The company’s shares have returned 14% to investors over the past five days. The company is working on rapid-acting antidepressants. These are used to treat patients with mental health conditions such as depression. The firm has a market cap of over $100 million and a 279% return on equity. It is based in the United Kingdom.
On June 25, Small Pharma Inc. (OTC: DMTTF) announced that it would be participating in two upcoming conferences on psychedelics in order to present and share the progress it had made in the assisted therapy department for depression.
In February this year, Small Pharma Inc. (OTC: DMTTF) had announced that it was beginning a clinical program related to DMT-assisted therapy. According to details provided by the firm, the program included a Phase I and Phase 11a trial of a leading drug candidate.
Just like COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK), Small Pharma Inc. (OTC: DMTTF) is a solid investment in the health sector.
9. Revive Therapeutics Ltd. (OTC: RVVTF)
Revive Therapeutics Ltd. (OTC: RVVTF) stock has returned 123% to investors over the past year. The firm operates as a life sciences company focusing on the development of drugs, like psychedelics, for treatment of rare disorders and infectious diseases. It is ranked ninth on our list of 10 best psychedelic stocks to buy now. The firm has a market cap of more than $135 million and a 52-week price high of $0.72 per share. It operates from Canada.
On June 25, Revive Therapeutics Ltd. (OTC: RVVTF) CEO Michael Frank announced that the company would begin trading on the OTCQB Market at the end of June, helping broaden the awareness and shareholder base in the United States.
Earlier that month, Revive Therapeutics Ltd. (OTC: RVVTF) had revealed an agreement with Supriya Lifescience in India for the manufacture, registration, and the marketing of a COVID-19-related drug named Bucillamine.
Revive Therapeutics Ltd. (OTC: RVVTF) is a top stock for the pharma industry, along with COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK).
8. Numinus Wellness Inc. (OTC: LKYSF)
Numinus Wellness Inc. (OTC: LKYSF) is a company that works closely on the development and delivery of psychedelic-assisted psychotherapy. It is placed eighth on our list of 10 best psychedelic stocks to buy now. The company’s shares have returned 282% to investors over the past twelve months. The firm has a market capitalization of over $165 million and posted more than $675,000 in annual revenue last year.
On July 12, Numinus Wellness Inc. (OTC: LKYSF) announced that authorities in Canada had approved a single-arm, open-label safety and feasibility study evaluating assisted therapy for post-traumatic stress disorder. Payton Nyquvest, the CEO of the firm, shared the news.
Earlier that month, Numinus Wellness Inc. (OTC: LKYSF) had announced that it would be purchasing the Neurology Centre of Toronto for $500,000 in cash and shares. The company plans to transform the centre into a treatment centre focusing on psychedelics.
Investors who are interested in COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK) should also check out Numinus Wellness Inc. (OTC: LKYSF).
7. Hollister Biosciences Inc. (OTC: HSTRF)
Hollister Biosciences Inc. (OTC: HSTRF) is ranked seventh on our list of 10 best psychedelic stocks to buy now. The stock has offered investors returns exceeding 78% over the course of the past twelve months. The firm primarily makes and sells cannabis products but also has interests in the psychedelic products business. It has a market cap of over $55 million and posted more than $30 million in revenue last year.
On June 1, Hollister Biosciences Inc. (OTC: HSTRF) posted earnings results for the first quarter of 2021, reporting a revenue of more than $23 million over the period, an increase of a whopping 2,331% compared to the revenue over the same period last year.
Last year, Hollister Biosciences Inc. (OTC: HSTRF) had entered the psychedelic industry with the purchase of AlphaMind Brands, a firm working on the development of psychedelic products. Carl Saling, the CEO of the firm, noted the fast growth in the psychedelic market at the time.
COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK) are some of the best stock options in the health industry, alongside Hollister Biosciences Inc. (OTC: HSTRF).
6. Field Trip Health Ltd. (OTC: FTRPF)
Field Trip Health Ltd. (OTC: FTRPF) is a firm concentrating on the development and delivery of psychedelic therapies. It is placed sixth on our list of 10 best psychedelic stocks to buy now. The company’s shares have offered investors returns exceeding % over the course of the past year. It is based in Toronto and has a market capitalization of over $300 million. The firm posted more than $750,000 in annual revenue last year.
Last month, Field Trip Health Ltd. (OTC: FTRPF) had announced that it had applied for a listing on the NASDAQ stock market in the United States. The firm had clarified that there would be no change to the shares, warrants, or the share structure as a result of the application.
In early May, Field Trip Health Ltd. (OTC: FTRPF) President Hannan Fleiman, while opening a field center, had said that psychedelic therapies were poised to play an important role in the treatment of mental health disorders that had sprung up as a result of the COVID-19 pandemic.
While COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK) dominate the conversations around novel therapies, Field Trip Health Ltd. (OTC: FTRPF) is making for itself in this regard as well.
5. Cybin Inc. (OTC: CLXPF)
Cybin Inc. (OTC: CLXPF) stock has returned more than 3,485% to investors in the past twelve months. The firm operates as a life sciences company concentrating on the development of psychedelic drugs. It is ranked fifth on our list of 10 best psychedelic stocks to buy now. Some of the leading drug candidates of the firm include CYB001 and CYB003. The former is a treatment for major depressive disorder while the latter aims to tackle alcohol use disorder.
In early July, Cybin Inc. (OTC: CLXPF) announced that it had entered into an agreement with TMS NeuroHealth Centers to establish Mental Health Centers of Excellence that would facilitate research and development of innovative psychedelic therapies.
In late March, Cybin Inc. (OTC: CLXPF) had revealed that it signed a
, a US-based biopharma firm, for use of Zydis orally disintegrating tablet technology. The new tech would be used as a delivery mechanism for the CYB003 drug being developed by Cybin.
4. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is placed fourth on our list of 10 best psychedelic stocks to buy now. The company’s shares have returned 19% to investors over the past twelve months. The firm is a New York-based biopharma company working on psychedelic medicines. It has a market capitalization of over $1.2 billion. The short interest on the stock is 1.14% and the share price touched a 52-week high of $5.77 in May.
On July 8, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that it had teamed up with Datavant, a health information technology company, to link clinical trial data to external data. The move is part of a plan to build broad and detailed datasets for further use.
In late June, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) was included in the FTSE Russell 3000 Index. The inclusion came just two months after the firm was listed on the NASDAQ exchange in the United States.
3. Seelos Therapeutics, Inc. (NASDAQ: SEEL)
Seelos Therapeutics, Inc. (NASDAQ: SEEL) stock has returned 146% to investors over the past year. The firm is a biotech company that focuses on the development of psychedelic drugs for the treatment of post-traumatic stress and some depressive disorders. It is ranked third on our list of 10 best psychedelic stocks to buy now. The company is based in New York. The stock has a short interest of 2.89%. The 52-week high for the stock is $6.6.
On July 7, Seelos Therapeutics, Inc. (NASDAQ: SEEL) posted encouraging results from a SLS-004 rodent study. Raj Mehra, the CEO of the firm, made the results public. The share price of the firm jumped more than 4% after the announcement.
At the end of the first quarter of 2021, 11 hedge funds in the database of Insider Monkey held stakes worth $47 million in Seelos Therapeutics, Inc. (NASDAQ: SEEL), up from 4 the preceding quarter worth $1.3 million.
2. Atai Life Sciences N.V. (NASDAQ: ATAI)
Atai Life Sciences N.V. (NASDAQ: ATAI) is a Germany-based biopharma company focusing on the development of psychedelic drugs. It is placed second on our list of 10 best psychedelic stocks to buy now. The company’s shares have offered investors returns exceeding 6.9% over the course of the past week. The company is backed by legendary investor Peter Thiel. It went public last month and was valued at $2.3 billion.
On July 13, Atai Life Sciences N.V. (NASDAQ: ATAI) stock was initiated at Buy or Overweight rating by prominent investment advisors like Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald, among others.
At the end of the first quarter of 2021, 3 hedge funds in the database of Insider Monkey held stakes worth $782,000 in Atai Life Sciences N.V. (NASDAQ: ATAI), up from 1 in the previous quarter worth $118,000.
1. COMPASS Pathways plc (NASDAQ: CMPS)
COMPASS Pathways plc (NASDAQ: CMPS) is ranked first on our list of 10 best psychedelic stocks to buy now. The stock has offered investors returns exceeding 10% over the course of the past five days. The company operates as a mental health care firm focusing on psychedelics. It is based in the United Kingdom and has a market cap of close to $1.5 billion. The company was founded last year.
In quarterly earnings for the fourth quarter of 2020, posted in March this year, COMPASS Pathways plc (NASDAQ: CMPS) reported earnings per share of -$0.52, missing market estimates by $0.16. On July 13, Bitritto-Garg initiated the stock at a Buy rating.
Out of the hedge funds being tracked by Insider Monkey, New York-based investment firm Perceptive Advisors is a leading shareholder in COMPASS Pathways plc (NASDAQ: CMPS) with 797,404 shares worth more than $29 million.
<<<
Insider Monkey
by Usman Kabir
July 14, 2021
https://finance.yahoo.com/news/10-best-psychedelic-stocks-buy-165743252.html
Psychedelic treatments for mental health disorders like depression, anxiety, and post-traumatic stress have revolutionized the industry in the past few years, helping the market for the novel therapies to grow from $2 billion in 2019, as per a report by Data Bridge Market Research, to almost $5 billion in 2020, according to a study by Research and Markets. The sector offers explosive growth potential, evidenced by the recent positive coverage of psychedelic stocks by investment research firms like Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald.
Some of the companies already making a big splash in the as yet small sector include COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), and Seelos Therapeutics, Inc. (NASDAQ: SEEL), among others. COMPASS Pathways plc (NASDAQ: CMPS) and Atai Life Sciences N.V. (NASDAQ: ATAI) recently debuted on the stock market, fetching billion dollar valuations, while Seelos Therapeutics, Inc. (NASDAQ: SEEL) has been soaring in trading the past few days on the back of positive results from a clinical study.
The success of these firms in the psychedelic market has attracted the attention of industry giants like Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK). These biopharma companies market different kinds of drugs for mental health disorders and sense a business opportunity as novel treatments for depression and anxiety become more widely accepted in the United States.
Investments in psychedelic startups have also increased in the past few months, with investors flocking to early stage psychedelic firms that are working on innovative new technologies to help psychedelics become more mainstream. Research institutions, like the Center for Psychedelic and Consciousness Research at John Hopkins University in Baltimore, which has already published more than 50 research papers on the subject, have also contributed to the industry. However, despite these advances, psychedelics remain a niche market in the pharma sector.
Investors looking to invest in the industry should be wary of certain challenges that the psychedelic companies will have to negotiate before unleashing their true growth potential. These challenges include an uphill legal battle to get approval for use of psychedelic substances in new drugs, a capacity-building campaign in the wider public to debunk the myths and stigma surrounding the use of psychedelics, as well as financial hurdles that an industry still in its infancy might face as it struggles for wider recognition.
The psychedelic industry has the potential to disrupt the biopharma sector in the coming years much like the rise of fintech has transformed the finance world. The entire hedge fund industry is feeling the reverberations of the changing financial landscape. Its reputation has been tarnished in the last decade, during which its hedged returns couldn’t keep up with the unhedged returns of the market indices.
With this context in mind, here is our list of the 10 best psychedelic stocks to buy now. These were ranked keeping in mind basic business fundamentals, hedge fund sentiment, and analyst ratings for each.
Best Psychedelic Stocks to Buy Now
10. Small Pharma Inc. (OTC: DMTTF)
Small Pharma Inc. (OTC: DMTTF) is placed tenth on our list of 10 best psychedelic stocks to buy now. The company’s shares have returned 14% to investors over the past five days. The company is working on rapid-acting antidepressants. These are used to treat patients with mental health conditions such as depression. The firm has a market cap of over $100 million and a 279% return on equity. It is based in the United Kingdom.
On June 25, Small Pharma Inc. (OTC: DMTTF) announced that it would be participating in two upcoming conferences on psychedelics in order to present and share the progress it had made in the assisted therapy department for depression.
In February this year, Small Pharma Inc. (OTC: DMTTF) had announced that it was beginning a clinical program related to DMT-assisted therapy. According to details provided by the firm, the program included a Phase I and Phase 11a trial of a leading drug candidate.
Just like COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK), Small Pharma Inc. (OTC: DMTTF) is a solid investment in the health sector.
9. Revive Therapeutics Ltd. (OTC: RVVTF)
Revive Therapeutics Ltd. (OTC: RVVTF) stock has returned 123% to investors over the past year. The firm operates as a life sciences company focusing on the development of drugs, like psychedelics, for treatment of rare disorders and infectious diseases. It is ranked ninth on our list of 10 best psychedelic stocks to buy now. The firm has a market cap of more than $135 million and a 52-week price high of $0.72 per share. It operates from Canada.
On June 25, Revive Therapeutics Ltd. (OTC: RVVTF) CEO Michael Frank announced that the company would begin trading on the OTCQB Market at the end of June, helping broaden the awareness and shareholder base in the United States.
Earlier that month, Revive Therapeutics Ltd. (OTC: RVVTF) had revealed an agreement with Supriya Lifescience in India for the manufacture, registration, and the marketing of a COVID-19-related drug named Bucillamine.
Revive Therapeutics Ltd. (OTC: RVVTF) is a top stock for the pharma industry, along with COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK).
8. Numinus Wellness Inc. (OTC: LKYSF)
Numinus Wellness Inc. (OTC: LKYSF) is a company that works closely on the development and delivery of psychedelic-assisted psychotherapy. It is placed eighth on our list of 10 best psychedelic stocks to buy now. The company’s shares have returned 282% to investors over the past twelve months. The firm has a market capitalization of over $165 million and posted more than $675,000 in annual revenue last year.
On July 12, Numinus Wellness Inc. (OTC: LKYSF) announced that authorities in Canada had approved a single-arm, open-label safety and feasibility study evaluating assisted therapy for post-traumatic stress disorder. Payton Nyquvest, the CEO of the firm, shared the news.
Earlier that month, Numinus Wellness Inc. (OTC: LKYSF) had announced that it would be purchasing the Neurology Centre of Toronto for $500,000 in cash and shares. The company plans to transform the centre into a treatment centre focusing on psychedelics.
Investors who are interested in COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK) should also check out Numinus Wellness Inc. (OTC: LKYSF).
7. Hollister Biosciences Inc. (OTC: HSTRF)
Hollister Biosciences Inc. (OTC: HSTRF) is ranked seventh on our list of 10 best psychedelic stocks to buy now. The stock has offered investors returns exceeding 78% over the course of the past twelve months. The firm primarily makes and sells cannabis products but also has interests in the psychedelic products business. It has a market cap of over $55 million and posted more than $30 million in revenue last year.
On June 1, Hollister Biosciences Inc. (OTC: HSTRF) posted earnings results for the first quarter of 2021, reporting a revenue of more than $23 million over the period, an increase of a whopping 2,331% compared to the revenue over the same period last year.
Last year, Hollister Biosciences Inc. (OTC: HSTRF) had entered the psychedelic industry with the purchase of AlphaMind Brands, a firm working on the development of psychedelic products. Carl Saling, the CEO of the firm, noted the fast growth in the psychedelic market at the time.
COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK) are some of the best stock options in the health industry, alongside Hollister Biosciences Inc. (OTC: HSTRF).
6. Field Trip Health Ltd. (OTC: FTRPF)
Field Trip Health Ltd. (OTC: FTRPF) is a firm concentrating on the development and delivery of psychedelic therapies. It is placed sixth on our list of 10 best psychedelic stocks to buy now. The company’s shares have offered investors returns exceeding % over the course of the past year. It is based in Toronto and has a market capitalization of over $300 million. The firm posted more than $750,000 in annual revenue last year.
Last month, Field Trip Health Ltd. (OTC: FTRPF) had announced that it had applied for a listing on the NASDAQ stock market in the United States. The firm had clarified that there would be no change to the shares, warrants, or the share structure as a result of the application.
In early May, Field Trip Health Ltd. (OTC: FTRPF) President Hannan Fleiman, while opening a field center, had said that psychedelic therapies were poised to play an important role in the treatment of mental health disorders that had sprung up as a result of the COVID-19 pandemic.
While COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), Abbott Laboratories (NYSE: ABT), and GlaxoSmithKline plc (NYSE: GSK) dominate the conversations around novel therapies, Field Trip Health Ltd. (OTC: FTRPF) is making for itself in this regard as well.
5. Cybin Inc. (OTC: CLXPF)
Cybin Inc. (OTC: CLXPF) stock has returned more than 3,485% to investors in the past twelve months. The firm operates as a life sciences company concentrating on the development of psychedelic drugs. It is ranked fifth on our list of 10 best psychedelic stocks to buy now. Some of the leading drug candidates of the firm include CYB001 and CYB003. The former is a treatment for major depressive disorder while the latter aims to tackle alcohol use disorder.
In early July, Cybin Inc. (OTC: CLXPF) announced that it had entered into an agreement with TMS NeuroHealth Centers to establish Mental Health Centers of Excellence that would facilitate research and development of innovative psychedelic therapies.
In late March, Cybin Inc. (OTC: CLXPF) had revealed that it signed a
4. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is placed fourth on our list of 10 best psychedelic stocks to buy now. The company’s shares have returned 19% to investors over the past twelve months. The firm is a New York-based biopharma company working on psychedelic medicines. It has a market capitalization of over $1.2 billion. The short interest on the stock is 1.14% and the share price touched a 52-week high of $5.77 in May.
On July 8, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that it had teamed up with Datavant, a health information technology company, to link clinical trial data to external data. The move is part of a plan to build broad and detailed datasets for further use.
In late June, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) was included in the FTSE Russell 3000 Index. The inclusion came just two months after the firm was listed on the NASDAQ exchange in the United States.
3. Seelos Therapeutics, Inc. (NASDAQ: SEEL)
Seelos Therapeutics, Inc. (NASDAQ: SEEL) stock has returned 146% to investors over the past year. The firm is a biotech company that focuses on the development of psychedelic drugs for the treatment of post-traumatic stress and some depressive disorders. It is ranked third on our list of 10 best psychedelic stocks to buy now. The company is based in New York. The stock has a short interest of 2.89%. The 52-week high for the stock is $6.6.
On July 7, Seelos Therapeutics, Inc. (NASDAQ: SEEL) posted encouraging results from a SLS-004 rodent study. Raj Mehra, the CEO of the firm, made the results public. The share price of the firm jumped more than 4% after the announcement.
At the end of the first quarter of 2021, 11 hedge funds in the database of Insider Monkey held stakes worth $47 million in Seelos Therapeutics, Inc. (NASDAQ: SEEL), up from 4 the preceding quarter worth $1.3 million.
2. Atai Life Sciences N.V. (NASDAQ: ATAI)
Atai Life Sciences N.V. (NASDAQ: ATAI) is a Germany-based biopharma company focusing on the development of psychedelic drugs. It is placed second on our list of 10 best psychedelic stocks to buy now. The company’s shares have offered investors returns exceeding 6.9% over the course of the past week. The company is backed by legendary investor Peter Thiel. It went public last month and was valued at $2.3 billion.
On July 13, Atai Life Sciences N.V. (NASDAQ: ATAI) stock was initiated at Buy or Overweight rating by prominent investment advisors like Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald, among others.
At the end of the first quarter of 2021, 3 hedge funds in the database of Insider Monkey held stakes worth $782,000 in Atai Life Sciences N.V. (NASDAQ: ATAI), up from 1 in the previous quarter worth $118,000.
1. COMPASS Pathways plc (NASDAQ: CMPS)
COMPASS Pathways plc (NASDAQ: CMPS) is ranked first on our list of 10 best psychedelic stocks to buy now. The stock has offered investors returns exceeding 10% over the course of the past five days. The company operates as a mental health care firm focusing on psychedelics. It is based in the United Kingdom and has a market cap of close to $1.5 billion. The company was founded last year.
In quarterly earnings for the fourth quarter of 2020, posted in March this year, COMPASS Pathways plc (NASDAQ: CMPS) reported earnings per share of -$0.52, missing market estimates by $0.16. On July 13, Bitritto-Garg initiated the stock at a Buy rating.
Out of the hedge funds being tracked by Insider Monkey, New York-based investment firm Perceptive Advisors is a leading shareholder in COMPASS Pathways plc (NASDAQ: CMPS) with 797,404 shares worth more than $29 million.
<<<
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
